MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...
XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud ...
PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (IPSC) (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies ...
HAMBURG, GERMANY / ACCESSWIRE / December 19, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has received a US$ 2.5 m ...
This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential ...
iXCells Biotechnologies Launches iPSCore™ Platform for Generating Highly Characterized iPSC-derived Human Cell Models i XCells Biotechnologies focuses on creating a broad portfolio of iPSC-derived off ...
Organoids are an important component of translational research, particularly for evaluating drug toxicity and tissue-specific responses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results